Last reviewed · How we verify

Antiplatelet Drug — Competitive Intelligence Brief

Antiplatelet Drug (antiplatelet-drug) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol. Area: Cardiovascular.

discontinued aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol Cardiovascular Live · refreshed every 30 min

Target snapshot

Antiplatelet Drug (antiplatelet-drug) — Pfizer Inc..

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Antiplatelet Drug TARGET antiplatelet-drug Pfizer Inc. discontinued aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antiplatelet Drug — Competitive Intelligence Brief. https://druglandscape.com/ci/antiplatelet-drug. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: